Faricimab

FDA Drug Profile — VABYSMO

Drug Details

Generic Name
Faricimab
Brand Names
VABYSMO
Application Number
BLA761235
Sponsor
Genentech, Inc.
NDC Codes
1
Dosage Forms
INJECTION, SOLUTION
Routes
INTRAVITREAL
Active Ingredients
FARICIMAB

Indications and Usage

1 INDICATIONS AND USAGE VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.3 ) 1.1 Neovascular (wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Macular Edema Following Retinal Vein Occlusion (RVO)